The analysis of the efficacy of patients with allergic rhinitis treated with specific immunotherapy.
- Author:
Junjie DING
;
Jianhua ZHANG
;
Bin CHEN
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Allergens;
administration & dosage;
Child;
Female;
Humans;
Immunotherapy;
Male;
Middle Aged;
Rhinitis, Allergic;
therapy;
Treatment Outcome;
Young Adult
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2014;28(5):293-296
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the efficacy and safety of standardized subcutaneous immunotherapy for dust mite in patients with allergic rhinitis.
METHOD:Using self-control methods, 35 cases with allergic rhinitis were treated with specific immunotherapy for 2 years. Symptom score and visual analogue scale (VAS) score were observed before treatment and 1 years, 2 years after treatment respectively.
RESULT:The symptoms, signs and VAS score of the 35 patients who were treated with specific immunotherapy after 1 year were significantly reduced than that before treatment, the differences were statistically significant (P < 0.05). The symptoms, signs and VAS score of the patients who completed 2 years' treatment, compared with that of pretreatment and 1 year treatment were significantly reduced, the differences were statistically significant (P < 0.05).
CONCLUSION:Standardized immunotherapy for dust mite is a safe, effective method for patients with perennial allergic rhinitis, which can be used as a routine treatment for allergic rhinitis. To further improve the therapeutic effect, immunotherapy should be continued for at least 2 years.
